AKT1 and breast cancer: This newly developed technique would therefore enable the more reliable and accurate testing of the clinical activity and responses of certain breast cancer therapies in patients, including the “endocrine (fulvestrant) therapy”, combined with the use of AZD5363, the pan-AKT inhibitor.